ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 145 filers reported holding ACLARIS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.60 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $227,304 | -33.9% | 33,183 | +0.0% | 0.00% | -50.0% |
| Q2 2023 | $344,097 | +136446.4% | 33,182 | +6.5% | 0.00% | 0.0% |
| Q1 2023 | $252 | -99.9% | 31,144 | +157.6% | 0.00% | 0.0% |
| Q2 2022 | $169,000 | -11.1% | 12,090 | +14.7% | 0.00% | +33.3% |
| Q3 2021 | $190,000 | +258.5% | 10,539 | -49.2% | 0.00% | +50.0% |
| Q3 2020 | $53,000 | -44.2% | 20,750 | -64.7% | 0.00% | -60.0% |
| Q2 2020 | $95,000 | +55.7% | 58,726 | 0.0% | 0.01% | 0.0% |
| Q1 2020 | $61,000 | -45.0% | 58,726 | -0.3% | 0.01% | 0.0% |
| Q4 2019 | $111,000 | +73.4% | 58,926 | 0.0% | 0.01% | +150.0% |
| Q3 2019 | $64,000 | -32.6% | 58,926 | +356.6% | 0.00% | 0.0% |
| Q4 2018 | $95,000 | -68.6% | 12,906 | +5.0% | 0.00% | -75.0% |
| Q4 2017 | $303,000 | – | 12,296 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |